Indication
Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: adults 50 years of age or older; adults 18 years of age or older at increased risk of HZ. The use of Shingrix should be in accordance with official recommendations.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Shingrix Polvo y Suspension Para Suspension InyectableSpain · 50 µgMarketed
- Shingrix Suspension Inyectable en Jeringa PrecargadaSpain · 50 µgAuthorised
- Shingrix 50 µg suspensie voor injectie in een voorgevulde spuitNetherlandsAuthorised
- Shingrix, poeder en suspensie voor suspensie voor injectieNetherlandsAuthorised